Otonomy, Inc. (Nasdaq: OTIC) announced that its Supplemental New Drug Application (sNDA) for the approval of OTIPRIO® as a treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE